OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	135
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	112
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	101
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	97
The first human acute myeloid leukemia genome ever fully sequenced	90
CD47 expression in acute myeloid leukemia varies according to genotype	73
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	64
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	63
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	60
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	59
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	57
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	53
Acute myeloid leukemia at first relapse: approaching the precipice	53
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	52
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	51
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	49
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	47
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	47
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	47
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	47
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	45
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	45
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	45
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	43
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	40

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience	40
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	40
Asparaginase-associated hyperammonemia	38
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	38
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	38
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	38
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	37
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	37
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	37
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	37
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	37
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	36
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	36